Abstract LBA32
Background
Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) significantly improved overall survival (OS, HR:0.52, P < 0.0001) and objective response rates (ORR, 26% vs 2%, P < 0.0001) in patients (pts) with BRAFV600E metastatic colorectal cancer (mCRC) compared with current standard of care. This analysis focuses on the triplet ((ENCO+CETUX+BINI) and doublet (ENCO+CETUX) arms.
Methods
The BEACON CRC study was a randomized, 3-arm, phase 3 study which evaluated triplet or doublet vs. investigator’s choice of irinotecan or FOLFIRI + CETUX in 665 pts with BRAFV600E mCRC. The triplet vs doublet efficacy comparison was a secondary endpoint (not formally powered). Analyses included efficacy (OS, ORR, depth of response, and progression-free survival [PFS]), multivariate modeling, safety, and quality of life (QOL) assessments (EORTC QOL Questionnaire (QLQ C30), Functional Assessment of Cancer Therapy Colon Cancer, EuroQol 5D 5L, and Patient Global Impression of Change).
Results
224 and 220 pts were randomized to triplet and doublet, respectively. Median overall survival for triplet and doublet was 9.0 (95%CI: 8.0, 11.4) and 8.4 months (95%CI: 7.5, 11.0), respectively (HR:0.79 [95%CI: 0.59, 1.06]). ORR was 26% (95%CI: 18%, 35%) for triplet and 20% (95%CI: 13%,29%) for doublet. For pts with 1 prior therapy, ORR was 34% (95%CI: 23, 47) for triplet and 22% (95%CI: 14, 33) for doublet. Waterfall plots indicated that depth of response favored triplet. Grade 3+ adverse events (AE) were 58% in triplet and 50% in doublet. Rates of discontinuation due to an AE were similar (triplet: 7%; doublet: 8%), with median relative dose intensity maintained for both arms. There were no differences in QOL across 4 instruments. Some toxicities occurred less frequently with the triplet.
Conclusions
In BEACON CRC, triplet and doublet showed encouraging activity in BRAFV600E mCRC. Data suggest that the triplet offers improved efficacy vs doublet with some additional manageable toxicity and no impact on overall QOL. Further follow-up will better define the relative benefits of the regimens.
Clinical trial identification
NCT02928224.
Editorial acknowledgement
Editorial assistance was provided by JD Cox and Mayville Medical Communications, with funding from Array Biopharma.
Legal entity responsible for the study
Array BioPharma Inc.
Funding
Array BioPharma Inc.
Disclosure
J. Tabernero: Advisory / Consultancy: Bayer; Advisory / Consultancy: Boehringer; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Novartis; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Taiho; Advisory / Consultancy: Merrimack; Advisory / Consultancy: Peptomyc; Advisory / Consultancy: Rafael Pharmaceuticals; Advisory / Consultancy: Symphogen; Advisory / Consultancy: Chugai Pharma; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Merus; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Array BioPharma; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BeiGene. A. Grothey: Honoraria (self): Elsevier; Honoraria (self): Aptitude Health; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Boston Biomedical; Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Advisory / Consultancy, Research grant / Funding (institution): Array BioPharma; Advisory / Consultancy: Guardant Health; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Eisai; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Boehringer Ingelheim. E. Van Cutsem: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Servier; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy: MSD; Advisory / Consultancy, Research grant / Funding (institution): Merck KGaA; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: AstraZeneca; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Ipsen; Research grant / Funding (institution): Merck. R. Yaeger: Research grant / Funding (institution), Travel / Accommodation / Expenses: Array BioPharma; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Novartis; Speaker Bureau / Expert testimony: Sysmex; Research grant / Funding (institution): Symphogen; Licensing / Royalties: Biocartis. H. Wasan: Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution): Merck KGaA; Honoraria (self), Speaker Bureau / Expert testimony: Celgene; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Sirtex Medical; Honoraria (self): Array BioPharma; Honoraria (self), Advisory / Consultancy: Shire; Honoraria (self): Genentech; Honoraria (self), Advisory / Consultancy: ERYTECH Pharma; Advisory / Consultancy: Roche; Advisory / Consultancy: Incyte; Speaker Bureau / Expert testimony: Servier; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): MSD. T. Yoshino: Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Sumitomo Dainppon; Research grant / Funding (institution): GSK. J. Desai: Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Research grant / Funding (institution): Bionomics; Advisory / Consultancy: Eisai; Advisory / Consultancy, Research grant / Funding (institution): BeiGene; Advisory / Consultancy: Ignyta; Research grant / Funding (institution): Roche; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Ipsen. F. Ciardiello: Advisory / Consultancy, Research grant / Funding (institution): Genentech; Advisory / Consultancy, Research grant / Funding (institution): Merck KGaA; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Amgen; Advisory / Consultancy: Pfizer; Research grant / Funding (institution): Servier; Research grant / Funding (institution): Symphogen; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Ipsen. N. Steeghs: Research grant / Funding (institution): AstraZeneca/MedImmune; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): AB Science; Research grant / Funding (institution): Deciphera; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Merus; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Incyte. H. Arkenau: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Servier; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Array BioPharma; Research grant / Funding (institution), Travel / Accommodation / Expenses: Iovance; Full / Part-time employment: SCRI. A. Gollerkeri: Full / Part-time employment: Pfizer Inc.. M. Pickard: Full / Part-time employment: Pfizer Inc.. K. Maharry: Full / Part-time employment: Pfizer Inc.. J.L. Christy-Bittel: Full / Part-time employment: Pfizer Inc.. L. Anderson: Full / Part-time employment: Pfizer Inc.. S. Kopetz: Shareholder / Stockholder / Stock options: MolecularMatch; Research grant / Funding (institution), Shareholder / Stockholder / Stock options: Navire ; Advisory / Consultancy: Roche; Advisory / Consultancy, Research grant / Funding (institution): Genentech; Advisory / Consultancy, Research grant / Funding (institution): EMD Serono; Advisory / Consultancy: Merck; Advisory / Consultancy: Karyopharm; Advisory / Consultancy: Amal Therapeutics; Advisory / Consultancy: Symphogen; Advisory / Consultancy: Holy Stone; Advisory / Consultancy, Research grant / Funding (institution): Biocartis; Advisory / Consultancy, Research grant / Funding (institution): Amgen; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Boehringer Ingelheim; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Guardian Health; Research grant / Funding (institution): Array BioPharma; Research grant / Funding (institution): MedImmune. All other authors have declared no conflicts of interest.
Resources from the same session
4878 - Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): novel mutated genes and their effect on response to therapy (Alliance)
Presenter: Federico Innocenti
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
5016 - Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase 3 IMPALA trial
Presenter: Ramon Salazar
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
Proffered Paper 2 – Gastrointestinal tumours, colorectal - Invited Discussant LBA32, LBA33 and 524O
Presenter: Alfredo Falcone
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast
1890 - MIRACLE: Green tea extract versus placebo for the prevention of colorectal adenomas: a randomized, controlled trial
Presenter: Thomas Seufferlein
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
Proffered Paper 2 – Gastrointestinal tumours, colorectal - Invited Discussant LBA34
Presenter: Andrew Chan
Session: Proffered Paper 2 – Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast